SB-228357: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 27: | Line 27: | ||
* [https://www.ncbi.nlm.nih.gov/pubmed/?term=SB-228357 PubMed articles on SB-228357] | * [https://www.ncbi.nlm.nih.gov/pubmed/?term=SB-228357 PubMed articles on SB-228357] | ||
* [https://www.google.com/search?q=SB-228357 Google search on SB-228357] | * [https://www.google.com/search?q=SB-228357 Google search on SB-228357] | ||
== SB-228357 == | |||
<gallery> | |||
File:SB-228357 structure.png|SB-228357 structure | |||
</gallery> | |||
Latest revision as of 01:14, 20 February 2025
SB-228357 is a serotonin receptor agonist that was discovered and developed by SmithKline Beecham. It is a potent and selective 5-HT4 receptor agonist, with a pKi of 9.5, and has been used in scientific research to study the function of the 5-HT4 receptor.
History[edit]
SB-228357 was first discovered and developed by the pharmaceutical company SmithKline Beecham. The compound was identified as a potent and selective 5-HT4 receptor agonist, which made it a valuable tool in scientific research to study the function of the 5-HT4 receptor.
Pharmacology[edit]
SB-228357 is a potent and selective 5-HT4 receptor agonist. The 5-HT4 receptor is one of the several different subtypes of the serotonin receptor, which is a group of G protein-coupled receptors that are targeted by a variety of drugs used in the treatment of various disorders, including depression, anxiety, and migraine.
Research[edit]
SB-228357 has been used in scientific research to study the function of the 5-HT4 receptor. The compound's potent and selective agonist activity at the 5-HT4 receptor makes it a valuable tool in this research.
